Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(64)

カスタマーフィードバック(13)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MkTJR5l1d3SxeHnjJGF{e2G7 MXWxNEBvVQ>? Mk\EO|IhcA>? NXzCVYtnTE2VTx?= M3nFb3BwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NXzlWnpjOjR7MEC4O|M>
HT-29 NELnfHREgXSxdH;4bYMhSXO|YYm= MWCxNEBvVQ>? M3PybFczKGh? MnzaSG1UVw>? M{fvcXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= M{PaRlI1QTByOEez
HT-29 NUX0RmI5S3m2b4TvfIlkKEG|c3H5 MYGxNEBvVQ>? NEXQNGg4OiCq NULm[m1nTE2VTx?= M{\nbnBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NGi0fpYzPDlyMEi3Ny=>
PC3 MV;LbY5ie2ViQYPzZZk> MWCxNFAhdk1? NIPKdlYyKGh? NYjvdJF1TE2VTx?= NGnJR4JRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> M1;BW|IyQTd6Nkiz
PC3 MVLLbY5ie2ViQYPzZZk> NVi4OXFrOTByIH7N NFnPNYwyKGh? Mlm0SG1UVw>? NXXRe3NFTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MWeyNVk4QDZ6Mx?=
PC3 NWDZO5hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTxNU42KM7:TR?= NXTDRZpKOSCq NFe0dIFFVVOR NHr0O4hKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= MnfVNlE6Pzh4OEO=
HEK293 MmXpSpVv[3Srb36gRZN{[Xl? NV30WmZQOTByIH7N MXK4JIg> MYnEUXNQ NFLnUYRKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NFX0bmUzOTV|OUOwNS=>
BT-20 NFXCbG5McW6jc3WgRZN{[Xl? NF73U48zOCEQvF2= MVHEUXNQ MVXEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MXSyNVM2OzV3MR?=
U937 MkjnRY51cWKjY4TldolidCCDc4PhfS=> MnXTOVAh|ryP M3jPcFQ5KGh? NIXyOYxFVVOR M4PPV2lv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= NYjuO49uOjFzNEKxNFY>
U937 Mk\3RY51cWKjY4TldolidCCDc4PhfS=> M2C0flUxKM7:TR?= M1\LOFQ5KGh? MX3EUXNQ NVf6cHpRTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= MlfWNlEyPDJzME[=
U937 MV3BcpRq[mGldHXybYFtKEG|c3H5 NHzxN5A2OCEQvF2= NGGxTJM1QCCq NYjXVmk5TE2VTx?= NV;Xc5NLTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NV3qXXhNOjFzNEKxNFY>
MCF-7 M4G0TWF2fG:yaHHnfUBCe3OjeR?= M4jkPFMxKG6P MnTlOEBp NWnGbmNnTE2VTx?= Mm\xTY5lfWOnczDheZRweGijZ4m= M4HGflIxODJ6MUO0
U87MG Mk\oT4lv[XOnIFHzd4F6 NYXx[phpOSEQvF2= NHXzUFM3KGh? MX7EUXNQ MmfwVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? MXixPVg1QDRyNB?=
U87MG MVLLbY5ie2ViQYPzZZk> NFP3NG0yKM7:TR?= NXrONotWPiCq MkXKSG1UVw>? M2jhbHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u NV7WVFl2OTl6NEi0NFQ>
U87MG M3XIN2tqdmG|ZTDBd5NigQ>? NFvKeHYyKM7:TR?= MVe2JIg> NYToeIZrTE2VTx?= MlX6SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NEfr[IUyQTh2OESwOC=>
U87MG MmnDT4lv[XOnIFHzd4F6 MoXHNUDPxE1? MnfPOkBp NUfYdHBiTE2VTx?= M1v1ZWRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? MVqxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb MYTBeZRweGijZ4mgRZN{[Xl? MVSwMlIh|ryP M2nzd|I1KGh? MWLEUXNQ NF2wOIFKdmS3Y3XzJIF2fG:yaHHnfS=> MmO2NVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 NHrKNXZCfXSxcHjh[5khSXO|YYm= MX2wMlIh|ryP NEf0eXQzPCCq NFG0d|hFVVOR NUfRcGR{UW6mdXPld{BifXSxcHjh[5k> M3;1[FE5OzlzOUS5
H4 MkT0SpVv[3Srb36gRZN{[Xl? M{PNcVAvOiEQvF2= MkKxNlQhcA>? NGjzUHpFVVOR NGnicGNKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ NEX4[XIyQDB{NEW4OC=>
HeLa M4TBSmZ2dmO2aX;uJGF{e2G7 NXvVfGlEOTByIH7N M{jBN|M3KGh? NHH0N5ZFVVOR MWHJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u MnfpNVc2PjN|OEW=
HeLa NV7oS|lTTnWwY4Tpc44hSXO|YYm= NIXqblIyODBibl2= M2jGZ|M3KGh? M4rCWmROW09? NHHwU2RKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? NHTFfVcyPzV4M{O4OS=>
HeLa MmH6SpVv[3Srb36gRZN{[Xl? MYOxNFAhdk1? NXi0Top4OzZiaB?= M1vyeGROW09? MWnJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NUX1NGNXOTd3NkOzPFU>
SYF NEK2cIpHfW6ldHnvckBCe3OjeR?= M4XKU|ExOCCwTR?= NVLa[mRbOjRiaB?= MYjEUXNQ MWDJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= MkjkNVc2PjN|OEW=
SYF MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDwNVAxKG6P M3jseFI1KGh? M4TW[mROW09? NYfmd|hVUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> M2rKfFE4PTZ|M{i1
HEK293T Ml3KRY51cX[rcnHsJGF{e2G7 Ml[xNUBvVQ>? M2fNSlQh\A>? NI\UdGFFVVOR NWfxUWg2UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> M4jibFE4PDh3NUCx
HEK293T MXnBcpRqfmm{YXygRZN{[Xl? MXqxJI5O M{\md|Qh\A>? Mnm1SG1UVw>? NVLzU|RNUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> NV\pXJN7OTd2OEW1NFE>
PBMC NXTJN4tkTnWwY4Tpc44hSXO|YYm= MYWxJI5O Mke3NVQh\A>? NWDtb5FETE2VTx?= NYTvdos{WmWmdXPld{BES1J3IHTlcpNqfHl? MYWxO|Q5PTVyMR?=
PBMC Mni1SpVv[3Srb36gRZN{[Xl? NEfHVVUyKG6P M3PTPFE1KGR? NH\udHNFVVOR NUSyR5FpTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? MmPsNVc1QDV3MEG=
HEK293 cells MX;LbY5ie2ViQYPzZZk> NWmzSXVkPTBibl2= NXvxfFkzPDVibXnu NWHRV3pCTE2VTx?= MYfJcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O NUDpdYYzOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc Mn\hSpVv[3Srb36gRZN{[Xl? NIDxd2kyODBibl2= NFyyW5M1KGh? NYna[mVuTE2VTx?= MljxTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> M{PISFE4OTJ6Mk[y
Human mixed lymphocyte MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HUUVUhdk1? M1KxdGROW09? MmDvTWM2OD1zLk[gcm0v MnnoNVYyQDV6NkW=
Lewis rat lymph node cells NXrMZoJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmwOUDPxE1? NXPRfnVtTE2VTx?= MorKTWM2OD1{Lk[g{txO MXKxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NVGxXFViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuxNEBvVQ>? M3;Jb|czKGh? NES1bo5FVVOR MXrJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P M1\IbFExODJzOUS4
MRK-nu-1 NV[2[lNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwOES1JJBO M2T4UnNCVkeHUh?=
OCUB-M M{DFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3sTWdrUUN3ME21MlI1KHCP MkXEV2FPT0WU
SF539 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnROItKSzVyPUGxMlYheE1? NV;ONm5CW0GQR1XS
ES4 MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjteZdKSzVyPUKxMlUheE1? MXjTRW5ITVJ?
RL95-2 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFyNzDwUS=> NXLQZXY{W0GQR1XS
LC-2-ad MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR{MzDwUS=> MWnTRW5ITVJ?
Daudi NWLmZXUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDiO4hWUUN3ME20N|QheE1? M4i3UHNCVkeHUh?=
NTERA-S-cl-D1 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzQO|BSUUN3ME20OFMheE1? MYnTRW5ITVJ?
OS-RC-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3zS45KSzVyPU[1NkBxVQ>? NH2xWYNUSU6JRWK=
VA-ES-BJ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjWTmEyUUN3ME23NlMheE1? M2TIZ3NCVkeHUh?=
GR-ST NXTi[Jk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTh2NjDwUS=> NGjWfItUSU6JRWK=
SW872 NEXjb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTh2NjDwUS=> NVj2bpZPW0GQR1XS
NOS-1 M{LIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD16N{GgdG0> MXjTRW5ITVJ?
MC116 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXVOFlYUUN3ME25PFUheE1? NXq5e48zW0GQR1XS
NCI-H1355 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nBN2lEPTB;MT6wNUBvVQ>? MmrIV2FPT0WU
RPMI-8226 M{TqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwMUmgcm0> NX;3bY1LW0GQR1XS
TE-15 NVf1bWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYToSFJyUUN3ME2xMlM3KG6P NUDGfoJpW0GQR1XS
Ramos-2G6-4C10 NGr6WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjq[ogxUUN3ME2xMlQ3KG6P MnHIV2FPT0WU
KU812 M1r4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7tXWJKSzVyPUKuNFEhdk1? NHnuZ2lUSU6JRWK=
EW-1 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0TWM2OD1{LkG3JI5O NFS0d41USU6JRWK=
KS-1 M3HuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\SPYlKSzVyPUKuOFUhdk1? M4Xmb3NCVkeHUh?=
SK-LMS-1 M4TUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M132XmlEPTB;Mj60PUBvVQ>? M2nhdXNCVkeHUh?=
TGBC1TKB NXrjRVlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIbXRKSzVyPUKuOlkhdk1? NVHEWmZmW0GQR1XS
TE-6 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjxTWM2OD1{Lke3JI5O MnrOV2FPT0WU
ETK-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDq[5ZMUUN3ME2yMlgzKG6P MUfTRW5ITVJ?
BE-13 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwOUmgcm0> M4DHdnNCVkeHUh?=
A3-KAW MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwOUmgcm0> NHn5cFVUSU6JRWK=
TE-10 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwMzDuUS=> MWXTRW5ITVJ?
DOHH-2 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrUW4tKSzVyPUOuN|Uhdk1? NUX0NVFNW0GQR1XS
ES6 NHm5NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTXTWM2OD1|LkSzJI5O Ml7BV2FPT0WU
OPM-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7GZ5FKSzVyPUSuNVUhdk1? MULTRW5ITVJ?
SH-4 NGeybIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17IOWlEPTB;ND6zOEBvVQ>? M33WcHNCVkeHUh?=
NB13 MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTkTWM2OD12LkO2JI5O MWfTRW5ITVJ?
HUTU-80 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBeYZKSzVyPUSuOFIhdk1? MlrNV2FPT0WU
CCRF-CEM NULEWFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PyVWlEPTB;ND65OEBvVQ>? MWTTRW5ITVJ?
TGBC24TKB NXvSWmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[5TWM2OD13LkWxJI5O NIHseXpUSU6JRWK=
697 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn0TWM2OD14LkK4JI5O MVXTRW5ITVJ?
J-RT3-T3-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZwNE[gcm0> NEX1Z3FUSU6JRWK=
KALS-1 NGn5NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG3epZWUUN3ME22MlU3KG6P MV3TRW5ITVJ?
no-10 NFKwdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTdwMkmgcm0> NF63[oRUSU6JRWK=
SK-NEP-1 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXqTWM2OD16Lke5JI5O NVHqd|JoW0GQR1XS
L-540 M3qwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HhSWlEPTB;MUCuOFIhdk1? Ml7lV2FPT0WU
JiyoyeP-2003 NIDORldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\sPG9WUUN3ME2xNE46PCCwTR?= NE[2[4RUSU6JRWK=
HH NH\0c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITHZmdKSzVyPUGxMlM6KG6P MmnMV2FPT0WU
SR M3TX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFzLkS1JI5O NFnaNm9USU6JRWK=
QIMR-WIL Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXIdY1KSzVyPUGxMlg2KG6P NYHCVpp2W0GQR1XS
A4-Fuk NVTRfoZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrDfG5OUUN3ME2xN{4yOiCwTR?= M4LSTHNCVkeHUh?=
CESS M3rYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrHTWM2OD1zMz6xN{BvVQ>? NFv2S|FUSU6JRWK=
KE-37 NUeyO4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF4LkC3JI5O M4HlcHNCVkeHUh?=
SK-UT-1 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Je2ZTUUN3ME2xOk45OSCwTR?= NGjucmhUSU6JRWK=
SIG-M5 NFXYZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\1NI9xUUN3ME2xO{4zPSCwTR?= MYXTRW5ITVJ?
HT NXrzVXluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnGZ29yUUN3ME2xO{43KG6P MVHTRW5ITVJ?
DEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\vSFNsUUN3ME2xO{46QSCwTR?= MXrTRW5ITVJ?
SK-PN-DW MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnDTWM2OD1{MD6yN{BvVQ>? M13kc3NCVkeHUh?=
RPMI-8402 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfpXYZKSzVyPUKxMlc4KG6P MUXTRW5ITVJ?
RPMI-6666 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID3[4NKSzVyPUK0MlQzKG6P NG\0V2NUSU6JRWK=
NCI-H720 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfLTJZiUUN3ME2yOU41OSCwTR?= M3q2XnNCVkeHUh?=
EW-16 M1;5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;mTWM2OD1{Nj64O{BvVQ>? MnjaV2FPT0WU
BL-70 NEe4SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvS[ZBKUUN3ME2yPE4{QCCwTR?= M4LtWHNCVkeHUh?=
SF126 NHm1bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNcWlEPTB;M{CuN|ghdk1? NInweXRUSU6JRWK=
BC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNzLkK2JI5O MmfGV2FPT0WU
MHH-PREB-1 M2DaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXsRm51UUN3ME2zNk41PCCwTR?= MnTBV2FPT0WU
A101D MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTN{Lk[yJI5O M1LlUHNCVkeHUh?=
NMC-G1 NV\1bmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN|Lk[3JI5O M1TsbXNCVkeHUh?=
LB1047-RCC NXvmZ4RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnVTWM2OD1|ND62PUBvVQ>? NVHmRZNPW0GQR1XS
EM-2 NHfMZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\yTWM2OD1|OD61N{BvVQ>? MkLwV2FPT0WU
COLO-684 NXrZTmFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN7Lkigcm0> Mm\xV2FPT0WU
Becker MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHHTWM2OD12MT6wOUBvVQ>? NXPoR|JlW0GQR1XS
BL-41 M2[0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3HXGRlUUN3ME20N{43PiCwTR?= M1HDW3NCVkeHUh?=
MDA-MB-134-VI NXq3Um1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;D[FR[UUN3ME20OE4xOiCwTR?= M2DSXHNCVkeHUh?=
L-363 NVO3OIJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W0XGlEPTB;NESuO|Mhdk1? NHLV[WlUSU6JRWK=
ECC4 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXUTWM2OD12ND63PEBvVQ>? MoK2V2FPT0WU
A388 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR2LkiyJI5O MUfTRW5ITVJ?
HEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrUOYJ[UUN3ME20PU44QSCwTR?= MWPTRW5ITVJ?
RKO MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPjTGtKSzVyPUWwMlI6KG6P M1TaTHNCVkeHUh?=
KINGS-1 M2HFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfsTXFKUUN3ME21NU42PSCwTR?= M{fScHNCVkeHUh?=
EB-3 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i3NmlEPTB;NUKuOlchdk1? M{nTe3NCVkeHUh?=
ARH-77 NIO5R5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjiOIk6UUN3ME21Nk45KG6P NXWxPG9oW0GQR1XS
GCIY NHHJV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH76fY9KSzVyPUWzMlQ3KG6P M3TBOHNCVkeHUh?=
NCI-H1304 NX;xR4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTV5LkKyJI5O NG[2NVBUSU6JRWK=
KARPAS-299 M{PDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTZzLkiyJI5O M4fDUnNCVkeHUh?=
IA-LM NUm5fYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjBOppKSzVyPU[4MlE{KG6P NVn2[mlOW0GQR1XS
GI-1 NXrkcVJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnPb|VKSzVyPUewMlM6KG6P NIjPXFhUSU6JRWK=
TE-11 NGDiS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2L1cmlEPTB;N{euNVchdk1? NYLUVJhOW0GQR1XS
LS-411N NHmwdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe3[nZKSzVyPUe3MlU4KG6P M{TqZXNCVkeHUh?=
no-11 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHoTWM2OD16Mz6yOEBvVQ>? NFfsNZhUSU6JRWK=
MV-4-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTh|LkezJI5O MWfTRW5ITVJ?
BV-173 M{HPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzNTWM2OD16Mz65O{BvVQ>? Mly2V2FPT0WU
CMK M17rZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q0e2lEPTB;OESuNVYhdk1? MlH5V2FPT0WU
LC4-1 NX\uSIZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\xZlVKSzVyPUi2MlczKG6P MVvTRW5ITVJ?
COR-L279 NV3pPZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLPd2dDUUN3ME24O{4zPSCwTR?= M4\0XHNCVkeHUh?=
NCI-H209 M136bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofETWM2OD16Nz60NUBvVQ>? MmL2V2FPT0WU
Raji NYX3fJB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF30dphKSzVyPUi5MlczKG6P NWnYSGpMW0GQR1XS
LB996-RCC NV25VohuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OzWGlEPTB;OUOuOFMhdk1? MYPTRW5ITVJ?
NCI-H526 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1viN2lEPTB;OUOuOVkhdk1? NELpNZdUSU6JRWK=
KGN M1fJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\G[WZKSzVyPUm2MlI6KG6P NH:zSWJUSU6JRWK=
MOLT-4 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\zUWlEPTB;OU[uO|khdk1? NUDofFh1W0GQR1XS
PF-382 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j2e2lEPTB;OU[uO|khdk1? NHjENHNUSU6JRWK=
BC-3 NFviS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTl7LkG4JI5O NIDGXmdUSU6JRWK=
KARPAS-422 NWDPeolET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFyMj6wPUBvVQ>? MU\TRW5ITVJ?
SBC-1 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyNz63OUBvVQ>? MneyV2FPT0WU
LC-1F MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFyOD6wOUBvVQ>? MYrTRW5ITVJ?
GB-1 M3fWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33rfGlEPTB;MUC5MlAzKG6P MW\TRW5ITVJ?
SNB75 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrKNnBKSzVyPUGxPU43QSCwTR?= MUHTRW5ITVJ?
BB65-RCC NULaepJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXiTWM2OD1zMUmuPVMhdk1? MnHCV2FPT0WU
NCI-N87 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXPZZk4UUN3ME2xNlEvQThibl2= MkTkV2FPT0WU
IST-MEL1 NIjlfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzibWJKSzVyPUGyNk4{QCCwTR?= NXXBdI1YW0GQR1XS
HOP-62 M4i3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDITWM2OD1zMk[uPFkhdk1? NXHnVGZJW0GQR1XS
ACN NWG0bZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID0RVFKSzVyPUG0Ok44PSCwTR?= NW\j[JRuW0GQR1XS
DMS-114 NYfuSno6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF3MD62O{BvVQ>? M3jtUXNCVkeHUh?=
MLMA MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrZSoo1UUN3ME2xOVkvQDhibl2= M2PNSHNCVkeHUh?=
HT-144 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTEWmlKSzVyPUG2OU41OyCwTR?= NVvPcpY2W0GQR1XS
C2BBe1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yzWWlEPTB;MU[3Mlc3KG6P Mn7lV2FPT0WU
L-428 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG1TWM2OD1zN{euO{BvVQ>? MlvOV2FPT0WU
DU-4475 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLRVlM5UUN3ME2xPFcvPjhibl2= NW\TPIIxW0GQR1XS
CP67-MEL NFjObGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmw[4Q4UUN3ME2xPVkvOzhibl2= M{LNcnNCVkeHUh?=
MEG-01 M4fYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISyZVBKSzVyPUKwNU46PiCwTR?= MXrTRW5ITVJ?
IST-SL2 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqzNVJMUUN3ME2yNFgvPjNibl2= NX;GRnFsW0GQR1XS
ES8 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\nRppKSzVyPUKyOU46PCCwTR?= MWLTRW5ITVJ?
COLO-800 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ|NT6yPEBvVQ>? MWPTRW5ITVJ?
MFH-ino NXXMUVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DZNWlEPTB;MkO1Mlg1KG6P Ml7sV2FPT0WU
OVCAR-4 NUfu[o5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon5TWM2OD1{M{euNlQhdk1? M2HjRnNCVkeHUh?=
PSN1 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnP[2lZUUN3ME2yOFIvPzFibl2= M1vYdHNCVkeHUh?=
EW-12 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTkTWM2OD1{NEOuNUBvVQ>? NUC0fmhCW0GQR1XS
HCC1599 NID3RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ4MT60O{BvVQ>? MoryV2FPT0WU
SJSA-1 NYLnZmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULKb3p{UUN3ME2yO|EvPDZibl2= NIjYe|VUSU6JRWK=
ST486 M2Szc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmxSGZxUUN3ME2yPVYvOTRibl2= MnLaV2FPT0WU
NOMO-1 M1nlZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nV[WlEPTB;M{CwMlIyKG6P MVrTRW5ITVJ?
MN-60 M{DVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofKTWM2OD1|MEWuN|Ihdk1? NYT3VJFkW0GQR1XS
HCC1187 NXz2NIZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOwNJFKSzVyPUOwO{4zPSCwTR?= MXrTRW5ITVJ?
SW982 NIn1XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfsPIdXUUN3ME2zNVQvPzVibl2= M3m2cXNCVkeHUh?=
LB647-SCLC NFn5eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WephKSzVyPUOyPE44OSCwTR?= MlXBV2FPT0WU
HC-1 M{PMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LmSmlEPTB;M{O1MlUhdk1? MYTTRW5ITVJ?
EHEB NWXwUmVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX2OFN1UUN3ME2zN|cvPTJibl2= MnrkV2FPT0WU
TUR MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T1eWlEPTB;M{[zMlk2KG6P NFHCfoVUSU6JRWK=
LU-139 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPDVXlwUUN3ME2zO|gvODJibl2= NFPPNVlUSU6JRWK=
NB1 NFrTOYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN6ND60OUBvVQ>? NICwU3ZUSU6JRWK=
BB30-HNC M4[0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfZPIdGUUN3ME2zPFgvOzJibl2= MWjTRW5ITVJ?
HAL-01 M1vVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWflbI05UUN3ME2zPFkvOjZibl2= NV;uNmN5W0GQR1XS
K5 M2qzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\rTI5tUUN3ME20NVEvOzdibl2= MmjoV2FPT0WU
MZ2-MEL Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDhTWM2OD12MUOuOlQhdk1? MXjTRW5ITVJ?
RXF393 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTBSWNKSzVyPUSxOk41PSCwTR?= M3nvc3NCVkeHUh?=
NCI-H1648 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjEbYI{UUN3ME20NVcvPTNibl2= NV\1dmI6W0GQR1XS
TE-12 M4\UOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTR|ND6yOkBvVQ>? NF70bnJUSU6JRWK=
EoL-1- MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD2e2lYUUN3ME20N|cvQThibl2= NFj4WHhUSU6JRWK=
JAR M1PSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLVXlF1UUN3ME20N|gvPjJibl2= NHnjV5VUSU6JRWK=
DSH1 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITVU2ZKSzVyPUS1PE46OSCwTR?= M3\YNXNCVkeHUh?=
NCI-H187 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfuN3d6UUN3ME20OlIvQDFibl2= M{frRnNCVkeHUh?=
HCE-4 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvZc3RRUUN3ME20O|cvPjZibl2= Mn\qV2FPT0WU
8-MG-BA MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXkUmJKSzVyPUW4NU42OiCwTR?= M3y4XnNCVkeHUh?=
KLE NHjoXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3yN4l2UUN3ME21PFUvOiCwTR?= MWrTRW5ITVJ?
KNS-42 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfpOVN3UUN3ME21PFYvQDFibl2= NWfn[odJW0GQR1XS
MSTO-211H Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZyOT63OEBvVQ>? MYDTRW5ITVJ?
GDM-1 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvTTlFKSzVyPU[xOE4xQSCwTR?= M13XPXNCVkeHUh?=
TE-1 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTZ2Nj6xNkBvVQ>? NUfWfGZlW0GQR1XS
BT-474 M{DNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnUdIdKSzVyPU[0O{4xPiCwTR?= NWP5SWt5W0GQR1XS
KARPAS-45 NGS4eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPKfXFKSzVyPU[0O{43KG6P NYK1ZY1tW0GQR1XS
MOLT-16 M4\LT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6xZlNKSzVyPU[0O{46OyCwTR?= NXzvRWJMW0GQR1XS
KURAMOCHI M2PSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZ3Nz61NUBvVQ>? NYPRd3p{W0GQR1XS
K-562 NGewfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHae|RmUUN3ME22OlkvPTFibl2= NHu0eFRUSU6JRWK=
EKVX M1vpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZ5Mj63NUBvVQ>? MYjTRW5ITVJ?
GAK NYnP[pR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTHSoVYUUN3ME22O|UvOyCwTR?= MVjTRW5ITVJ?
NCI-SNU-5 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq5XI52UUN3ME22PVAvODFibl2= M{XZXHNCVkeHUh?=
NCI-H2126 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni0TWM2OD15Mk[uPFchdk1? Mkj4V2FPT0WU
CTV-1 NVPIdVByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTd2ND65JI5O NXq0RoNbW0GQR1XS
SW962 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTxTWM2OD15NEiuOFQhdk1? MWjTRW5ITVJ?
MONO-MAC-6 NV;teWdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTd3Nj65N{BvVQ>? NVjL[YZyW0GQR1XS
NCI-H748 M1TKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KxdmlEPTB;N{W4Mlk6KG6P M4PvOnNCVkeHUh?=
NCI-H524 M2rwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXLTWM2OD15OECuO|Mhdk1? MUPTRW5ITVJ?
LS-123 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrhdGN6UUN3ME23PVUvPjlibl2= MoXPV2FPT0WU
NB7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zY[GlEPTB;OEG0MlE1KG6P MlrTV2FPT0WU
LS-1034 M3\yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT3Zno2UUN3ME24NlgvQThibl2= MYnTRW5ITVJ?
TE-5 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTvTWM2OD16OEOuOVYhdk1? NV[3bo1JW0GQR1XS
A704 NYKwTW1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXuSINwUUN3ME24PVkvOTVibl2= NIX6UIhUSU6JRWK=
TK10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTlzNj6wN{BvVQ>? M3PlfXNCVkeHUh?=
NCI-H345 NIP3e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnqc|BKSzVyPUm0N{4zOiCwTR?= NEKzXJRUSU6JRWK=
CGTH-W-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXsTWM2OD17NEiuNVMhdk1? NUTGPJpxW0GQR1XS
NCI-H510A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHsc2NXUUN3ME25PFUvOTJibl2= NGHTVWpUSU6JRWK=
NCI-H1963 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjUcWFiUUN3ME2xMlA{Ojl{IN88US=> NHzzdYpUSU6JRWK=
SCC-3 NXjYc5VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMEO0NVQh|ryP NV22WHp3W0GQR1XS
EW-11 NXnxXlM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLXTWM2OD1zLkC4O|Q{KM7:TR?= MY\TRW5ITVJ?
CPC-N NFTCPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXifYhbUUN3ME2xMlA5QCEQvF2= M3XYc3NCVkeHUh?=
NCI-H1417 M13xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH1UHZKSzVyPUGuNVIzPiEQvF2= NE\nSZFUSU6JRWK=
DG-75 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMU[yPFUh|ryP M4rxOnNCVkeHUh?=
HD-MY-Z Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nEXWlEPTB;MT6xOlQyPiEQvF2= Mn70V2FPT0WU
ATN-1 NH3YcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfMTWM2OD1zLkK2NlA6KM7:TR?= M{G3ZnNCVkeHUh?=
KM-H2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwMk[0NFgh|ryP M2nwfHNCVkeHUh?=
NCI-H2081 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W0R2lEPTB;MT6yOlY{PyEQvF2= MUTTRW5ITVJ?
HL-60 NFzTWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnpTWM2OD1zLkK2PVU6KM7:TR?= MVTTRW5ITVJ?
DB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PxW2lEPTB;MT6yO|I1OiEQvF2= MYPTRW5ITVJ?
NCI-H1522 NUXre3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwMki4PFch|ryP M1;3NXNCVkeHUh?=
AM-38 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f4cGlEPTB;MT6zNFczKM7:TR?= NW\1WItTW0GQR1XS
NCI-H446 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe1Wo9KSzVyPUGuN|IyOjFizszN M4\URnNCVkeHUh?=
SU-DHL-1 NVjCe|RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG2TWM2OD1zLkOyPFAyKM7:TR?= NU\ZW21HW0GQR1XS
NH-12 M3XTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3rPG1IUUN3ME2xMlM3Ozd2IN88US=> M4DtbHNCVkeHUh?=
DMS-79 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fjO2lEPTB;MT6zOlg3PiEQvF2= NWH0fHNHW0GQR1XS
NCI-H716 NUnie2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL0NZZKSzVyPUGuN|g6QDZizszN NWD5Z5ZPW0GQR1XS
ML-2 NVfiXIpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCTWM2OD1zLkSxOVI6KM7:TR?= MnTwV2FPT0WU
NB10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwNE[2N|Ih|ryP MVTTRW5ITVJ?
ONS-76 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe0d|VKSzVyPUGuOVM2PjlizszN NUDoN5R7W0GQR1XS
LOUCY MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGzSGVoUUN3ME2xMlU1PjV5IN88US=> NVnhfI1yW0GQR1XS
SCLC-21H NXu0[IkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDlUHBKSzVyPUGuOVg2QDJizszN MmHrV2FPT0WU
TGW NWHEdYJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\v[mh4UUN3ME2xMlY{QTd3IN88US=> NYK5O5U3W0GQR1XS
LXF-289 M3LzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDBN4ZrUUN3ME2xMlc{OjZ6IN88US=> NEPCXodUSU6JRWK=
BB49-HNC NYrW[HFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL1NnZ{UUN3ME2xMlc{PTh4IN88US=> Mk\sV2FPT0WU
NCI-H747 NGnxfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3TUndoUUN3ME2xMlc2OzR4IN88US=> NWnpfllqW0GQR1XS
LU-165 NFH3emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCwTWM2OD1zLki0PVg3KM7:TR?= NHXHWFdUSU6JRWK=
OMC-1 NWntOFFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwOUWwOlYh|ryP MUnTRW5ITVJ?
RCC10RGB NHvxSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHW0d4VKSzVyPUGuPVU5OTdizszN M1yw[nNCVkeHUh?=
SW684 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jlWWlEPTB;MT65OlA6QSEQvF2= NVTmXoRoW0GQR1XS
TE-8 NUfDWos3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwMEW1OVkh|ryP MYfTRW5ITVJ?
SK-N-DZ NH7lTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXIR4hzUUN3ME2yMlE{Ojd2IN88US=> M1zUcHNCVkeHUh?=
EVSA-T NXnVWJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwMUezNVUh|ryP NHvJcm5USU6JRWK=
KASUMI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwMUi4NVUh|ryP M{H4e3NCVkeHUh?=
NKM-1 M4fmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfRRm9QUUN3ME2yMlI2PDd{IN88US=> MlTvV2FPT0WU
CAL-148 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\vT49KSzVyPUKuN|M3OTRizszN MXfTRW5ITVJ?
NCI-H64 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnB[nNKSzVyPUKuN|QzOzJizszN M1\4UXNCVkeHUh?=
KNS-81-FD M2XyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\MUpl4UUN3ME2yMlM3PjJizszN NXzpeppkW0GQR1XS
KM12 MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrlUJRKSzVyPUKuOFA5OzlizszN MmHGV2FPT0WU
SW954 NWnCWWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j6cmlEPTB;Mj60O|c4QSEQvF2= NFrZUJNUSU6JRWK=
NCI-H1395 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Lr[GlEPTB;Mj61NlY1PSEQvF2= NED3NlZUSU6JRWK=
DJM-1 NFTxRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33SVWlEPTB;Mj62NFY{KM7:TR?= NWfBUZFkW0GQR1XS
COLO-668 NFf3WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HSd2lEPTB;Mj64NlY6PSEQvF2= NGrSXpBUSU6JRWK=
NCI-H1436 NEHNRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqyTWM2OD1{Lki1OlE2KM7:TR?= MXzTRW5ITVJ?
LB2241-RCC NVTMO5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC0NG9bUUN3ME2yMlg3QDN7IN88US=> NHS3N5dUSU6JRWK=
GT3TKB NE\J[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjaSXBKSzVyPUKuPFkxPTVizszN MmO3V2FPT0WU
COLO-824 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzPR2ZpUUN3ME2yMlg6PzZ6IN88US=> NXG5dJZrW0GQR1XS
ES1 NIfMTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLrTWM2OD1{Lki5PFc6KM7:TR?= MmfyV2FPT0WU
LB771-HNC NEKxfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf0cFFxUUN3ME2yMlkxQTR4IN88US=> NILidI9USU6JRWK=
GI-ME-N MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jwUGlEPTB;Mz6wNFkxPCEQvF2= MXLTRW5ITVJ?
NALM-6 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwMEC5N|Mh|ryP NXztfnBJW0GQR1XS
LU-134-A NFvGRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[3dJNOUUN3ME2zMlA2PDJ3IN88US=> M{W0NXNCVkeHUh?=
DMS-153 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofmTWM2OD1|LkC1PFI1KM7:TR?= M3H1[nNCVkeHUh?=
MZ1-PC NUfSO41WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHMVmNKSzVyPUOuNFkxPzhizszN MWPTRW5ITVJ?
NCI-H1155 NVvDUHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO2Wm1sUUN3ME2zMlEyPjFizszN MY\TRW5ITVJ?
CAS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;oTWM2OD1|LkGzO|A4KM7:TR?= NYG1cZJVW0GQR1XS
D-502MG NGPldoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHEPZlKSzVyPUOuNVQ{QSEQvF2= NIfRdoJUSU6JRWK=
NCI-H2141 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTWWGNSUUN3ME2zMlE4PDV{IN88US=> NYjnSZlmW0GQR1XS
NB6 NH7D[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC4OlNVUUN3ME2zMlE5OjV7IN88US=> MV;TRW5ITVJ?
NCCIT M2i2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17JTGlEPTB;Mz6yNVgxQSEQvF2= M3;TR3NCVkeHUh?=
NB69 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH71WFZKSzVyPUOuN|E5QTFizszN M3qyVHNCVkeHUh?=
JVM-2 NVH2O|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXQ[ZV3UUN3ME2zMlM3PDN|IN88US=> NVv6UnN2W0GQR1XS
K052 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXOTWM2OD1|LkO3PVY5KM7:TR?= NVvjWoo4W0GQR1XS
HCC2157 NI\he4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNwNUOyNlgh|ryP M{\XN3NCVkeHUh?=
KMOE-2 NIn6fmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37IUGlEPTB;Mz61OFI1OiEQvF2= NWPnPWVoW0GQR1XS
SF268 NIexNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iyTmlEPTB;Mz63NVU2PCEQvF2= MlTrV2FPT0WU
CHP-126 M4SwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNwN{[0OVgh|ryP M2[zUHNCVkeHUh?=
CP66-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHlW3hnUUN3ME2zMlc6ODl2IN88US=> NXzW[XdIW0GQR1XS
NCI-H69 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIWYpkUUN3ME20MlAyQTN4IN88US=> MmDJV2FPT0WU
A253 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37JWWlEPTB;ND6wNlExOSEQvF2= M3jCOXNCVkeHUh?=
NB14 NWfVZnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnznTWM2OD12LkGwOFc6KM7:TR?= MoDQV2FPT0WU
NCI-H1694 NVfoT3loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD12LkGzNVEzKM7:TR?= MWrTRW5ITVJ?
NCI-H2196 NHHrRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFryUWtKSzVyPUSuNVcyPjlizszN MWrTRW5ITVJ?
TE-9 NVLTeYprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrmTWM2OD12LkG3OVgzKM7:TR?= NHvZRoJUSU6JRWK=
D-283MED MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHuTWM2OD12LkG4PFQh|ryP NV[0blhpW0GQR1XS
OCI-AML2 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X6RmlEPTB;ND6xPVQ5QSEQvF2= M4nFUXNCVkeHUh?=
D-263MG Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xle2lEPTB;ND6yNlk3OSEQvF2= NH7YUJVUSU6JRWK=
MPP-89 NWexbHQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXzTWM2OD12LkK3N|A1KM7:TR?= M3\5PHNCVkeHUh?=
LAMA-84 NE\1XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTRwM{C0NlEh|ryP NW\nXWV[W0GQR1XS
LB373-MEL-D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[2SmI4UUN3ME20MlM3Pzh7IN88US=> MoHlV2FPT0WU
UACC-257 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\hdmlEPTB;ND6zPVU{PCEQvF2= MUHTRW5ITVJ?
MC-CAR NWfUe3N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzxc|JiUUN3ME20MlQ{QTlizszN NVzjc2tIW0GQR1XS
COLO-320-HSR NYLSbJNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwNES0Nlch|ryP MnnJV2FPT0WU
P30-OHK MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwNk[1PFEh|ryP NETZXHZUSU6JRWK=
UACC-812 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPqSndmUUN3ME20MlY6OTZzIN88US=> NUHlNWpVW0GQR1XS
CTB-1 NFWyT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPrTWM2OD12LkexOVU2KM7:TR?= M2frPHNCVkeHUh?=
ALL-PO M2Hwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjKZ5RlUUN3ME20Mlg1ODd5IN88US=> NHjRSm1USU6JRWK=
SK-MEL-2 M1rtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XVd2lEPTB;ND64Olk2PSEQvF2= NWjlO4ViW0GQR1XS
TC-YIK M4eydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnWR4VKSzVyPUSuPVc6PDJizszN M2[xVHNCVkeHUh?=
NCI-H1882 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;6cXVKSzVyPUWuNFIxODFizszN M13VXHNCVkeHUh?=
MHH-CALL-2 MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjRbHpxUUN3ME21MlA2ODR{IN88US=> NGrNR2RUSU6JRWK=
U-87-MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfVV3lKSzVyPUWuNFk1PjZizszN NXe4SVZEW0GQR1XS
NCI-H1092 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDxPWZKSzVyPUWuNlY2PTVizszN NVLWUItbW0GQR1XS
TE-441-T M1y4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\aTWM2OD13LkK3PFIh|ryP M2n0b3NCVkeHUh?=
SK-MEL-1 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi3U|ZKSzVyPUWuNlkxPDRizszN NYXZOFV6W0GQR1XS
EW-22 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH2TWM2OD13LkK5OFY3KM7:TR?= M2HYfnNCVkeHUh?=
MZ7-mel MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ITWM2OD13LkSwOlkyKM7:TR?= NEHPeoNUSU6JRWK=
LP-1 NXuxe3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXJTWM2OD13LkSxNlkyKM7:TR?= NFvDdVhUSU6JRWK=
NCI-SNU-16 NGCwSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTVwNkSwO|Qh|ryP NUHweJB5W0GQR1XS
LU-65 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz5c4lnUUN3ME21Mlc3Ozd|IN88US=> NWruWWFnW0GQR1XS
CW-2 NHT5OYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFVWFKSzVyPUWuPFU6PTlizszN NYHkcVRWW0GQR1XS
WSU-NHL NITiSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHSTWM2OD13Lkm1NVc1KM7:TR?= NG\KR5ZUSU6JRWK=
IST-MES1 NWPuRnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnl[VlKSzVyPUWuPVU1PDNizszN M1rWdHNCVkeHUh?=
U-266 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTVwOUiyNFIh|ryP M2HJdXNCVkeHUh?=
TALL-1 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dnd2lEPTB;Nj6xOFY5QCEQvF2= MV;TRW5ITVJ?
Calu-6 NV3ZOmplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\BTWM2OD14LkG1N|E3KM7:TR?= MkfDV2FPT0WU
MMAC-SF NFXSUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO3TWM2OD14LkG4OVU3KM7:TR?= Moi5V2FPT0WU
NCI-H82 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7GTWM2OD14LkKwOFg6KM7:TR?= NHfpOG9USU6JRWK=
RS4-11 NG\EVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL1UlVKSzVyPU[uNlU5QTdizszN MXTTRW5ITVJ?
SNU-C2B M3;Xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW3S3lKSzVyPU[uOFA6PjlizszN MU\TRW5ITVJ?
BOKU MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PNeGlEPTB;Nj60O|U6PyEQvF2= M2TQb3NCVkeHUh?=
C8166 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOyO25IUUN3ME22MlU2QTF{IN88US=> M4\1d3NCVkeHUh?=
D-247MG NU\hNZd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC2TWM2OD15LkC0N|Q4KM7:TR?= MXvTRW5ITVJ?
EW-18 M2TEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH5[FRKSzVyPUeuNFczQTJizszN NIn1T|ZUSU6JRWK=
KG-1 M{\BZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C2OmlEPTB;Nz62Nlc{QCEQvF2= Mn\4V2FPT0WU
REH MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PCN2lEPTB;Nz62PFExQSEQvF2= MnPpV2FPT0WU
U-698-M NFr1RXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXzcmdKSzVyPUeuPFQ{OTVizszN NYfvWZNZW0GQR1XS
KP-N-RT-BM-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrzTWM2OD15LkmzNFI6KM7:TR?= MUfTRW5ITVJ?
MS-1 NGLEWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmyTWM2OD15Lkm2NFQyKM7:TR?= M1LZd3NCVkeHUh?=
SNU-C1 NETKU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m1cWlEPTB;Nz65PFE6OiEQvF2= Ml3TV2FPT0WU
SK-MM-2 M3\Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRThwMk[wOlUh|ryP MnzXV2FPT0WU
LAN-6 NX3McINqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe4TW5KSzVyPUiuN|AxODFizszN NF;rVGRUSU6JRWK=
NEC8 NHq2NmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRThwM{C2PVEh|ryP NU\RWlA{W0GQR1XS
NCI-H1770 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXmTZNoUUN3ME24MlM5ODB{IN88US=> NVTNS4tEW0GQR1XS
D-336MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnMPGI5UUN3ME24MlQxOTF4IN88US=> NUW3OHlLW0GQR1XS
COLO-829 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy2W|BVUUN3ME24MlQ5QDd7IN88US=> MUXTRW5ITVJ?
LS-513 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon4TWM2OD16LkW5OVk6KM7:TR?= NXW4UHA{W0GQR1XS
YT NGLiTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjWNYZKSzVyPUiuOlI1OjdizszN NUnaWll7W0GQR1XS
EW-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PjZ2lEPTB;OD63OlU1KM7:TR?= NILle3hUSU6JRWK=
IST-SL1 NXT4c5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7wRpNKSzVyPUiuPFY2PDNizszN MYjTRW5ITVJ?
CA46 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvUT2c{UUN3ME24Mlk2ODl6IN88US=> Ml3xV2FPT0WU
NCI-H1838 NEPQVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml76TWM2OD16Lkm4OlAzKM7:TR?= M{[3XXNCVkeHUh?=
NCI-H719 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPwTWM2OD17LkK1Nlc6KM7:TR?= NWXq[|RDW0GQR1XS
HCE-T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXMTWM2OD17LkOwPFUyKM7:TR?= Mn[xV2FPT0WU
A498 NWDhU4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzBTWM2OD17LkO2NVI1KM7:TR?= MmTwV2FPT0WU
LB831-BLC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTTXHJKSzVyPUmuO|Y2OjFizszN NGfJ[JJUSU6JRWK=
SKM-1 NGLEW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DuemlEPTB;OT64OVk3OyEQvF2= Ml65V2FPT0WU
THP-1 NE\ESVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTlwOU[5NVgh|ryP M2fuVXNCVkeHUh?=
SHP-77 M4H3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6wcZZKSzVyPUGwMlQxPyEQvF2= M3P2Z3NCVkeHUh?=
EW-3 M2fiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW1V2dKSzVyPUGwMlYzQDlizszN NYDySINXW0GQR1XS
KY821 M2nBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvQTWM2OD1zMD63OlMh|ryP NXLXfYoxW0GQR1XS
NCI-SNU-1 NILh[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvTWM2OD1zMT6wNlE4KM7:TR?= NUnvV5NxW0GQR1XS
HCC2218 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFzLkO5PFYh|ryP MXfTRW5ITVJ?
IM-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYToRXVqUUN3ME2xNU42OTB4IN88US=> MXrTRW5ITVJ?
NCI-H889 M2HTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlyyTWM2OD1zMT61N|E{KM7:TR?= NGLnc3VUSU6JRWK=
HDLM-2 M{n5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLzTWM2OD1zMj60NVU6KM7:TR?= NE\JSpZUSU6JRWK=
LB2518-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInq[5FKSzVyPUGyMlY5OTVizszN NVfmRpdiW0GQR1XS
NCI-H23 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nod2lEPTB;MUOuNlQzPSEQvF2= Mme1V2FPT0WU
NB17 M1TN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRSVB[UUN3ME2xN{41PTd7IN88US=> Mn\5V2FPT0WU
NCI-H322M NETWSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLFOYlKSzVyPUG0MlQxPjhizszN M2jacXNCVkeHUh?=
SUP-T1 NYfkZ4ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPNTWM2OD1zND60NVMh|ryP MVPTRW5ITVJ?
ES3 M2HoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF3LkC3NFMh|ryP NYXJWHhLW0GQR1XS
ES5 NGTVWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfMUo5KSzVyPUG1MlA4QDdizszN NEKwOZdUSU6JRWK=
NCI-H1650 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETLfGJKSzVyPUG1MlQ6PzlizszN Ml3aV2FPT0WU
NCI-H226 MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOzTWM2OD1zNT64O|Y5KM7:TR?= NIjuPVRUSU6JRWK=
COR-L88 NHnkfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn1fZdKSzVyPUG2MlMyPCEQvF2= NHjybohUSU6JRWK=
SCC-15 M2P2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\UTmlEPTB;MU[uN|g3QSEQvF2= NXrjb|ZiW0GQR1XS
GOTO MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[5PYJuUUN3ME2xOk41Pzl|IN88US=> Mk\QV2FPT0WU
SIMA M2\uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW3bFhKSzVyPUG2MlQ5ODJizszN M13QOXNCVkeHUh?=
NCI-H1299 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF5LkG1PVEh|ryP M{THVXNCVkeHUh?=
NCI-H1581 NH31cmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M174N2lEPTB;MUeuOFIyQSEQvF2= MYnTRW5ITVJ?
MHH-NB-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5U2lEPTB;MUeuPVY5OyEQvF2= MXnTRW5ITVJ?
MFM-223 NXrTNlNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTrTWM2OD1zOD6wOVM5KM7:TR?= M4G2OXNCVkeHUh?=
ES7 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPld3d6UUN3ME2xPE42PDNzIN88US=> MXzTRW5ITVJ?
JVM-3 NXnhXIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz4XnlYUUN3ME2xPE44OTdizszN M{j4fHNCVkeHUh?=
RL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\yTWM2OD1{MD6zPFgh|ryP NHLCdYtUSU6JRWK=
EC-GI-10 M3jQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJzLkKwOFEh|ryP M3vJWnNCVkeHUh?=
LNCaP-Clone-FGC M3ewUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rZVWlEPTB;MkGuOlc3QCEQvF2= Moe3V2FPT0WU
IMR-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Hwc2lEPTB;MkGuPFQ6PCEQvF2= MWjTRW5ITVJ?
KP-N-YS NXTzZ|BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnHTWM2OD1{MT64O|Uh|ryP NVvINo9ZW0GQR1XS
Mo-T NVL3bVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nvOmlEPTB;MkKuNlE5PSEQvF2= MnLFV2FPT0WU
NCI-H128 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\yZYxGUUN3ME2yN{42QDV|IN88US=> MVfTRW5ITVJ?
RH-1 M4[wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZPYxKSzVyPUKzMlc5PjZizszN M1eyZnNCVkeHUh?=
NCI-H2171 M{PNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jsOGlEPTB;MkSuNlQ5PSEQvF2= M{XPXHNCVkeHUh?=
RPMI-8866 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fEXGlEPTB;Mk[uO|QzKM7:TR?= NVnwXGo3W0GQR1XS
SK-N-FI MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJ5LkO4NVEh|ryP NITJWXVUSU6JRWK=
LOXIMVI NHPVO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLoTWM2OD1{Nz64NFUyKM7:TR?= MkPJV2FPT0WU
P31-FUJ NFq4WHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjKSJBsUUN3ME2zNU42Ozd2IN88US=> NYntTFBvW0GQR1XS
KMS-12-PE NGnWWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXuTWM2OD12OT61N|AzKM7:TR?= M1[4e3NCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID